170 related articles for article (PubMed ID: 37591955)
1. AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.
Okamoto K; Ando T; Izumi H; Kobayashi SS; Shintani T; Gutkind JS; Yanamoto S; Miyauchi M; Kajiya M
Oncogene; 2023 Sep; 42(39):2869-2877. PubMed ID: 37591955
[TBL] [Abstract][Full Text] [Related]
2. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
3. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.
Ando T; Arang N; Wang Z; Costea DE; Feng X; Goto Y; Izumi H; Gilardi M; Ando K; Gutkind JS
Commun Biol; 2021 Nov; 4(1):1237. PubMed ID: 34725466
[TBL] [Abstract][Full Text] [Related]
4. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
6. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
8. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.
Faraji F; Ramirez SI; Anguiano Quiroz PY; Mendez-Molina AN; Gutkind JS
Cells; 2022 Apr; 11(8):. PubMed ID: 35456049
[TBL] [Abstract][Full Text] [Related]
9. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.
Zhang J; Ji JY; Yu M; Overholtzer M; Smolen GA; Wang R; Brugge JS; Dyson NJ; Haber DA
Nat Cell Biol; 2009 Dec; 11(12):1444-50. PubMed ID: 19935651
[TBL] [Abstract][Full Text] [Related]
10. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
11. AXL mediates resistance to cetuximab therapy.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
[TBL] [Abstract][Full Text] [Related]
12. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
13. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance.
Lee JE; Park HS; Lee D; Yoo G; Kim T; Jeon H; Yeo MK; Lee CS; Moon JY; Jung SS; Kim JO; Kim SY; Park DI; Park YH; Lee JC; Oh IJ; Lim DS; Chung C
Biochem Biophys Res Commun; 2016 May; 474(1):154-160. PubMed ID: 27105908
[TBL] [Abstract][Full Text] [Related]
14. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
[TBL] [Abstract][Full Text] [Related]
15. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
16. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
17. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
[TBL] [Abstract][Full Text] [Related]
18. The potential role of YAP in head and neck squamous cell carcinoma.
Shin E; Kim J
Exp Mol Med; 2020 Aug; 52(8):1264-1274. PubMed ID: 32859951
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional co-activator YAP: A new player in head and neck cancer.
Segrelles C; Paramio JM; Lorz C
Oral Oncol; 2018 Nov; 86():25-32. PubMed ID: 30409308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
